Clinical Trial Update: Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors [Phase 2]

View source ↗

Summary

Phase 2 trial results evaluate a bortezomib-based graft-versus-host disease prophylaxis strategy after allogeneic transplantation in patients without matched re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma
• Myelodysplastic Syndrome

Drugs mentioned

• Bortezomib (Velcade) (Bortezomib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Leukemia, Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2014-03-31